Hemostats Market Size, Share, Forecast, & Trends Analysis by Type Form Application End User

Description

List of Tables

Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User- Global Forecast to 2031

The hemostat market is projected to reach $5.32 billion by 2031 at a CAGR of 6.9% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. However, allergic reactions caused by the material used in making hemostats restrain the growth of this market.

Furthermore, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to generate growth opportunities for the players operating in this market. However, the high manufacturing cost for hemostasis and the high cost of advanced antimicrobial hemostatic agents are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the hemostat market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).

Among all the types studied in this report, in 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostat market. The segment's large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.

Among all the applications studied in this report, in 2024, the surgery segment is expected to account for the larger share of the hemostat market. The largest market share of this segment is attributed to the increasing number of surgeries, rise in the number of accidents, and growing demand for cosmetic/plastic surgeries. For instance, according to the World Health Organization (WHO), in 2021, yearly, 4.4 million people died from injuries, 3.16 million died from accidental wounds, and 1.25 million died from violence-related injuries globally.

Among all the forms studied in this report, in 2024, the matrix and gel segment is expected to account for the largest share of the hemostat market. The segment's large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.

Among all the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostat market. The growing number of surgeries conducted in hospitals, the use of hemostats for control of minor, moderate, and severe bleeding in operating rooms, the availability of different forms of hemostats used for surgical procedures, and the availability of favorable reimbursement policies are some of the major factors driving the growth of this segment.

An in-depth analysis of the geographical scenario of the hemostat market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 32.9% of the hemostat market. In the region in 2024, the U.S. is expected to account for the largest share of the hemostat market in North America. The large share of this regional market is attributed to the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.

Scope of the Report:

Hemostat Market Assessment-by Type

Absorbable Hemostats
- Mechanical or Passive Agents
Gelatin-based Hemostat
Collagen Hemostat
Oxidized Regenerated Cellulose Hemostat
- Flowable and Active Agents
Thrombin-based Hemostat
Combination Hemostat
- Other Absorbable Hemostat
Non-absorbable Hemostats
- Fibrin Sealants
- Synthetic Sealants
- Hemostatic Gauze
- Hemostatic Forceps

Hemostat Market Assessment-by Application

Surgery
- Orthopedic Surgery
- General Surgery
- Gynecology Surgery
- Cardiovascular Surgery
- Neurosurgery
- Plastic Surgery
- Other Surgeries
Dental Treatments
Traumatic Injury

Hemostat Market Assessment-by Form

Sponges and Dressings
Sheets and Pads
Powder
Matrix and Gel
Tools

Hemostat Market Assessment-by End User

Hospitals & Clinics
Ambulatory Surgical Centers
Nursing Homes

Hemostat Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041150

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection and Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study

3. Executive Summary

4. Factors Affecting Market Growth

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Volume of Surgical Procedures Performed
- 4.2.2. High Research and Development in Surgical Devices Sector
- 4.2.3. Increasing Rate of Accidents
- 4.2.4. Increase in Cesarean Deliveries, Fatal Injuries, and Organ Transplantation
- 4.2.5. Increasing R&D Activities by Government Organizations and the Private Sector
- 4.2.6. Rising Government Healthcare Spending
- 4.2.7. Growing Adoption of Minimally Invasive Surgical Procedures
4.3. Restraints
- 4.3.1. Allergic Reactions Caused by the Material Used in Making Hemostats
4.4. Opportunities
- 4.4.1. Increasing Need to Control Blood Loss by Using Advanced Hemostats
- 4.4.2. Advancements in Dental Hemostatic Agents
- 4.4.3. Increasing Demand for Preloaded Applicators and Ready-to-Use Hemostats
4.5. Challenges
- 4.5.1. High Manufacturing Cost for Hemostasis
- 4.5.2. High Cost of Advanced Antimicrobial Hemostatic Agents
4.6. Trends
- 4.6.1. Biopolymer-based Hemostats
- 4.6.2. Dual-Action Hemostatic Technology
4.7. Factor Analysis
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Case Studies
4.11. Porter's Five Forces Analysis

5. Hemostats Market Assessment-by Type

5.1. Overview
5.2. Absorbable Hemostats
- 5.2.1. Mechanical or Passive Agents
  - 5.2.1.1. Gelatin-based Hemostat
  - 5.2.1.2. Collagen Hemostat
  - 5.2.1.3. Oxidized Regenerated Cellulose Hemostat
- 5.2.2. Flowable and Active Agents
  - 5.2.2.1. Thrombin-based Hemostat
  - 5.2.2.2. Combination Hemostat
- 5.2.3. Other Absorbable Hemostats
5.3. Non-absorbable Hemostats
- 5.3.1. Fibrin Sealants
- 5.3.2. Synthetic Sealants
- 5.3.3. Hemostatic Gauze
- 5.3.4. Hemostatic Forceps

6. Hemostats Market Assessment-by Application

6.1. Overview
6.2. Surgery
- 6.2.1. Orthopedic Surgery
- 6.2.2. General Surgery
- 6.2.3. Gynecology Surgery
- 6.2.4. Cardiovascular Surgery
- 6.2.5. Neurosurgery
- 6.2.6. Plastic Surgery
- 6.2.7. Other Surgeries
6.3. Dental Treatments
6.4. Traumatic Injury

7. Hemostats Market Assessment-by Form

7.1. Overview
7.2. Sponges and Dressings
7.3. Sheets and Pads
7.4. Powder
7.5. Matrix and Gel
7.6. Tools

8. Hemostats Market Assessment-by End User

8.1. Overview
8.2. Hospitals & Clinics
8.3. Ambulatory Surgical Centers
8.4. Nursing Homes

9. Hemostats Market Assessment-by Geography

9.1. Overview
9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Switzerland
- 9.3.7. Netherlands
- 9.3.8. Rest of Europe (RoE)
9.4. Asia-Pacific
- 9.4.1. Japan
- 9.4.2. China
- 9.4.3. India
- 9.4.4. Australia
- 9.4.5 South Korea
- 9.4.6. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa

10. Competition Analysis

10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

11.1. Baxter International Inc. (U.S.)
11.2. Pfizer Inc. (U.S.)
11.3. B. Braun Melsungen AG (Germany)
11.4. C. R. Bard, Inc.(U.S.)
11.5. Integra LifeSciences (U.S.)
11.6. Medtronic plc (Ireland)
11.7. CSL Behring (U.K.)
11.8. Gelita Medical GmbH (Germany)
11.9. Grifols, S.A. (Spain)
11.10. Abbott Laboratories (U.S.)
11.11. CryoLife (U.S.)
11.12. Ethicon, Inc. (U.S.) (a subsidiary of Johnson & Johnson.)
11.13. Medtronic plc (Ireland)
11.14. Becton, Dickinson and Company (BD) (U.S.)
11.15. Advanced Medical Solutions Group plc (U.K.)

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

12.1. Available Customization
12.2. Related Reports